Author Manuscript Published OnlineFirst on May 29, 2018; DOI: 10.1158/0008-5472.CAN-17-3124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Combined c-Met/Trk inhibition overcomes resistance to CDK4/6 inhibitors in Glioblastoma Inan Olmez1,*, Ying Zhang2, Laryssa Manigat1, Mouadh Benamar3,4, Breanna Brenneman1, Ichiro Nakano5, Jakub Godlewski6, Agnieszka Bronisz6, Jeongwu Lee7, Tarek Abbas3,4, Roger Abounader2, and Benjamin Purow1 1Department of Neurology, University of Virginia, Charlottesville, VA 22908, USA. 2Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA 22908, USA. 3Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA 22908, USA. 4Department of Radiation Oncology, University of Virginia, Charlottesville, VA 22908, USA. 5Department of Neurosurgery, University of Alabama, Birmingham, AL 35233, USA. 6Department of Neurosurgery, Brigham and Women’s Hospital, Boston, MA 02115, USA. 7Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA. Running title: c-Met/Trk activation drives resistance to CDK4/6 inhibition *Corresponding Author: Inan Olmez, M.D., University of Virginia, Old Medical School, Room 4885, 21 Hospital Drive, Charlottesville, VA 22908, USA. P: 434-892-6664, F: 434-982-4467,
[email protected] or
[email protected] Disclosure of Potential Conflicts of Interest: Authors declare no competing financial interests. Word count: 4080 Number of figures and tables: 5 figures and 1 table 1 Downloaded from cancerres.aacrjournals.org on September 24, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 29, 2018; DOI: 10.1158/0008-5472.CAN-17-3124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.